Molecular and immunohistochemical p53 status in liposarcoma and malignant fibrous histiocytoma. Identification of seven new mutations for soft tissue sarcomas
✍ Scribed by Helge Taubert; Peter Würl; Axel Meye; Dieter Berger; Barbara Thamm; Karsten Neumann; Raoul Hinze; Hannelore Schmidt; Friedrich-Wilhelm Rath
- Publisher
- John Wiley and Sons
- Year
- 1995
- Tongue
- English
- Weight
- 920 KB
- Volume
- 76
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
✦ Synopsis
Background. p53 mutations are the most frequently observed tumor-related genetic changes. Mutational analysis concerns mostly carcinomas and is not comprehensive for soft tissue sarcomas. Among soft tissue sarcomas, malignant fibrous histiocytoma (MFH) and liposarcoma represent the most frequent tumor types. Most of the few identified mutations for soft tissue sarcomas are localized in the core domain of p53. A correlation between p53 positive immunoreactivity, missense mutations, and a poor prognosis is generally assumed. However, the character of p53 mutations and their functional importance for the clinical process is still unknown.
Methods. Sixty-two soft tissue sarcoma samples were investigated for the presence of p53 mutations and for p53 immunoreactivity. Exons 4-9 of the p53 gene were amplified from genomic DNA with the polymerase chain reaction. A prescreen for mutations was performed by nonradioactive single strand conformation polymorphism analysis; striking cases were sequenced directly. For an evaluation of the immunohistochemical status, five p53 antibodies were used.
Results. In 10 tumor samples 7 new p53 mutations and one polymorphism were identified. Mutations were From the Institute of *Pathology, the tSurgical Clinic, and the